KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Current Assets (2016 - 2025)

Amgen has reported Current Assets over the past 17 years, most recently at $29.1 billion for Q4 2025.

  • Quarterly results put Current Assets at $29.1 billion for Q4 2025, changed 0.09% from a year ago — trailing twelve months through Dec 2025 was $29.1 billion (changed 0.09% YoY), and the annual figure for FY2025 was $29.1 billion, changed 0.09%.
  • Current Assets for Q4 2025 was $29.1 billion at Amgen, up from $27.9 billion in the prior quarter.
  • Over the last five years, Current Assets for AMGN hit a ceiling of $48.5 billion in Q3 2023 and a floor of $18.5 billion in Q1 2022.
  • Median Current Assets over the past 5 years was $26.8 billion (2024), compared with a mean of $28.0 billion.
  • Biggest five-year swings in Current Assets: skyrocketed 145.21% in 2023 and later crashed 44.79% in 2024.
  • Amgen's Current Assets stood at $19.4 billion in 2021, then rose by 14.45% to $22.2 billion in 2022, then skyrocketed by 36.72% to $30.3 billion in 2023, then dropped by 4.29% to $29.0 billion in 2024, then rose by 0.09% to $29.1 billion in 2025.
  • The last three reported values for Current Assets were $29.1 billion (Q4 2025), $27.9 billion (Q3 2025), and $26.7 billion (Q2 2025) per Business Quant data.